Hypersensitivity, Milk Clinical Trial
Official title:
Pilot Study on the Efficacy and Safety of an Oral Desensitization Protocol at the Onset of Food Allergy
NCT number | NCT03586388 |
Other study ID # | RC 18/12 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | March 2015 |
Est. completion date | June 2017 |
Verified date | July 2018 |
Source | IRCCS Burlo Garofolo |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Cow's milk (CM) allergy is the most frequent food allergy in the first years of life, with
prevalence rates estimated in the range of 2-3%.
The elimination of CM is the mainstay of treatment, but accidental exposure to CM proteins is
not uncommon, with a considerable risk of severe allergic reactions.
Recent evidence suggests that early oral exposure in young children may protect to the
development of allergy. On the same way, strategies have been developed for the use of oral
exposure as immunotherapy for the treatment of children with established food allergy even if
available data on the use of oral immunotherapy in infants with food allergy are very
limited.
The aim of this study is to evaluate the feasibility of an oral immunotherapy protocol,
started in the first year of life, in children with CM allergy.
Status | Completed |
Enrollment | 73 |
Est. completion date | June 2017 |
Est. primary completion date | December 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 3 Months to 12 Months |
Eligibility |
Inclusion Criteria: • children between 3-12 months with CM allergy (defined as the association of typical clinical manifestations in the first hour after CM ingestion and evidence of sensitization of CM proteins on both skin prick test and specific serum IgE levels) Exclusion Criteria: - children with not IgE-mediated clinical manifestations - children with a known immunodeficiency |
Country | Name | City | State |
---|---|---|---|
Italy | Institute for Maternal and Child Health - IRCCS Burlo Garofolo- | Trieste |
Lead Sponsor | Collaborator |
---|---|
IRCCS Burlo Garofolo |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | number of children that completed the home oral immunotherapy protocol, reaching clinical tolerance | Clinical tolerance defined as the achievement of a dose of 150 ml of CM or a corresponding dose of dairy products | 6 months | |
Secondary | Clinical reactions experienced by children at home | Number and types, communicated by parents at a dedicated telephone number. | 6 months | |
Secondary | Serum levels of specific IgE | Comparison in serum levels of specific IgE between baseline and the end of the protocol, hypothesizing a decrease of IgE levels after OFC | 6 months | |
Secondary | Serum levels of specific IgG4 | Comparison in serum levels of specific IgG4 between baseline and the end of the protocol, hypothesizing an increase of IgG4 levels after OFC | 6 months |